Published in Gene Therapy Weekly, December 25th, 1995
Through the agreement, DuPont Merck could invest up to $55 million in Mitotix in the form of equity, research, development and clinical milestone payments.
The collaboration is initially focusing on three of Mitotix's proprietary molecular targets. Under the terms of the agreement, DuPont Merck receives exclusive worldwide rights to develop...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.